notificationsアラート設定
~
検索条件をクリア

アブストラクト

Title 免疫チェックポイント阻害薬を含む標準治療 〜消化器がん〜
Subtitle 特集「ここまできたがん免疫療法」
Authors 岡本渉
Authors (kana)
Organization 広島大学病院がん治療センター
Journal 杏林医学会雑誌
Volume 51
Number 3
Page 207-213
Year/Month 2020 / 9
Article 報告
Publisher 杏林医学会
Abstract 「要旨」免疫チェックポイント阻害剤とくに抗PD-1/PD-L1抗体は, 幅広い癌種において有効性が確認され, 適応癌種が拡大している. 消化器癌に対して, 本邦では化学療法既治療の食道癌, 胃癌, 大腸癌の一部に抗PD-1抗体単剤療法が使用可能である(2020年8月現在). また, 肝細胞癌, 胃癌, 食道癌, 大腸癌の一部においては, 初回治療における免疫チェックポイント阻害剤単剤または併用療法の有効性が示されており, 本邦でも近く使用可能となることが見込まれる. 免疫チェックポイント阻害剤は, 有効な症例には長期の効果が得られるものの, 有効な患者は限定的であることから, 免疫チェックポイント阻害剤の治療選択に有益なバイオマーカーの同定が望まれる.
Practice 臨床医学：一般
Keywords 消化器癌, ニボルマブ, ペムブロリズマブ, MSI
  • 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
download全文ダウンロード(0.95MB)

参考文献

  • 1) Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y: Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy(ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20 : 1506-1517, 2019.
    pubmed
  • 2) https://www.esophagus.jp/files/attraction3_nivolumab_comment.pdf
  • 3) Kojima T, Muro K, Francois E, Hsu CH, Moriwaki T, Kim SB, Lee SH, Bennouna J, Kato K, Lin S, Qin SQ, Ferreira P, Doi T, Adenis A, Enzinger PC, Shah MA, Wang R, Bhagia P, Kang SP, Metges JP: Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study. DOI: 10. 1200/JCO. 2019. 37. 4_suppl. 2 Journal of Clinical Oncology 37, no. 4_suppl.
  • 4) http://www.jgca.jp/guideline/fifth/category2-d.html#H1_D
  • 5) Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT: Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens(ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390 : 2461-2471, 2017.
残りの22件を表示する
  • 6) Josep Tabernero, Eric Van Cutsem, Yung-Jue Bang, Charles S. Fuchs, Lucjan Wyrwicz, Keun Wook Lee, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, Hugo Raul Castro Salguero, Wasat Mansoor, Maria Ignez Freitas Melro Braghiroli, Eray Goekkurt, Joseph Chao, Zev A. Wainberg, Uma Kher, Sukrut Shah, SoonMo Peter Kang, Kohei Shitara: Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction(G/GEJ) adenocarcinoma: The Phase III KEYNOTE-062 study. DOI: 10. 1200/JCO. 2019. 37. 18_suppl. LBA4007 Journal of Clinical Oncology 37, no. 18_suppl.
  • 7) https://news.bms.com/press-release/corporatefinancial-news/checkmate-649-phase-3-trial-evaluating-opdivo-nivolumab-plus-c
  • 8) https://www.ono.co.jp/jpnw/PDF/n20_0514.pdf
  • 9) Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL: Phase I study of single-agent anti-programmed death-1(MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28 : 3167-75, 2010.
    pubmed
  • 10) Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL: Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 19 : 462-8, 2013.
  • 11) Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 : 2443-54, 2012.
    pubmed
  • 12) Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr: PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372 : 2509-20, 2015.
    pubmed
  • 13) Le DT, Kim TW, Van Cutsem E, Geva R, Jager D, Hara H, Burge M, O'Neil B, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Elez E, Al-Batran SE, Boland PM, Crocenzi T, Atreya CE, Cui Y, Dai T, Marinello P, Diaz LA Jr, Andre T: Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol 38 : 11-19, 2020.
    pubmed
  • 14) Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, Andre T: Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer(CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18 : 1182-1191, 2017.
    pubmed
  • 15) Andre T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CA, Smith DM, Rocio Garcia-Carbonero, Benavides M, Gibbs P, Christelle De La Fouchardiere, Rivera F, Elez E, Bendell JC, Le DT, Yoshino T, Yang P, Mohammed Zulfiqar Husain Farooqui, Marinello P, Diaz LA: Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study. DOI: 10. 1200/JCO. 2020. 38. 18_suppl. LBA4 Journal of Clinical Oncology 38, no. 18_suppl.
  • 16) J. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, J. Raoul, S. Zeuzem, et al. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma(HCC) DOI: 10. 1200/jco. 2007. 25. 18_suppl. lba1 Journal of Clinical Oncology 25, no. 18_suppl.
  • 17) Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 : 378-90, 2008.
  • 18) Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL; KEYNOTE-240 investigators: Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 38 : 193-202, 2020.
    pubmed
  • 19) AL. Cheng, S. Qin, M. Ikeda, P. Galle, M. Ducreux, A. Zhu, T. Y. Kim, M. Kudo, V. Breder, P. Merle, A. Kaseb, D. Li, W. Verret, Z. Xu, S. Hernandez, J. Liu, C. Huang, S. Mulla, H. Y. Lim, R. Finn: LBA3-IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab(atezo)+bevacizumab(bev) vs sorafenib(Sor) as first treatment(tx) for patients(pts) with unresectable hepatocellular carcinoma(HCC). DOI : https://doi.org/10.1093/annonc/mdz446.002
  • 20) Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382 : 1894-1905, 2020.
    pubmed
  • 21) Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS Jr, Rafii S, Schwartz JD: Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26 : 2992-8, 2008.
    pubmed
  • 22) Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjord JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Jager N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, Lopez-Otin C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdes-Mas R, van Buuren MM, van 't Veer L, Vincent-Salomon A, Waddell N, Yates LR; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR: Signatures of mutational processes in human cancer. Nature 500 : 415-21, 2013.
    pubmed
  • 23) Teng MW, Ngiow SF, Ribas A, Smyth MJ: Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res 75 : 2139-45, 2015.
  • 24) Akagi K, Oki E, Taniguchi H, Nakatani K, Aoki D, Kuwata T, Yoshino T: Nationwide large-scale investigation of microsatellite instability status in more than 18,000 patients with various advanced solid cancers. DOI: 10. 1200/JCO. 2020. 38. 4_suppl. 803 Journal of Clinical Oncology 38, no. 4_suppl.
  • 25) Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357 : 409-413, 2017.
    pubmed
  • 26) Kim RD, Chung V, Alese OB, El-Rayes BF, Li D, Al-Toubah TE, Schell MJ, Zhou JM, Mahipal A, Kim BH, Kim DW: A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. JAMA Oncol 6 : 1-8, 2020.
    pubmed
  • 27) Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, Kelley RK, Ros W, Italiano A, Nakagawa K, Rugo HS, de Braud F, Varga AI, Hansen A, Wang H, Krishnan S, Norwood KG, Doi T: Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer, 2020. doi: 10. 1002/ijc. 33013. Online ahead of print.
はじめての方へ
個人／法人会員登録のご案内